Lanreotide Injection 120 mg/0.5 mL
Cipla recalls Lanreotide Injection 120 mg/0.5 mL over sterility assurance concerns.
Consumers who have this product should stop using it and contact their healthcare provider for guidance. Return the product to the place of purchase or follow the instructions provided by Cipla USA for a refund or replacement.
Recall at a glance
- Quantity recalled
- 54,583 syringes
Why it was recalled
Cipla USA is recalling Lanreotide Injection, 120 mg/0.5 mL, pre-filled syringes due to a lack of assurance of sterility. The recall follows an FDA observation at the contract manufacturing site regarding deficiencies in the visual inspection procedure.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Lanreotide InjectionStrength: 120 mg
| NDC / UPC | Recall # |
|---|---|
| NDC 69097-906-67 | D-0423-2026 |
| NDC 69097-870-67 | D-0422-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other recent recalls from Cipla USA, Inc.
Editorial summary by Recall Canary · summary updated 2026-09-03 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification